At-Home Telehealth-Supported Subcutaneous Ketamine Therapy for Safety, Feasibility, and Clinical Outcomes in Adults With Moderate to Severe Depression, Anxiety, or Posttraumatic Stress Disorder in a Large, Heterogeneous Cohort in the United States: Retrospective Cohort Study - Takeaways - MDSpire

Telehealth-Enabled Subcutaneous Ketamine Treatment at Home: Evaluating Safety, Feasibility, and Clinical Outcomes in Adults with Moderate to Severe Depression, Anxiety, or PTSD in a Diverse U.S. Cohort - A Retrospective Study

  • By

  • Acacia C Parks

  • Amanda L Woodward

  • Robert D Henry

  • Kristin A Arden

  • Leonardo Vando

  • Jack Swain

  • Bishal Lamichhane

  • July 20, 2026

Share

  • 1

    Major depressive disorder, generalized anxiety disorder, and PTSD are leading causes of global disability, with significant treatment gaps in the U.S.

  • 2

    Access to mental health professionals in the U.S. is limited, with only 28% of the population having adequate access to necessary care.

  • 3

    The COVID-19 pandemic accelerated the adoption of telemedicine, highlighting existing gaps in mental health treatment access.

  • 4

    Fewer than 50% of patients with depression respond to psychotherapy, and similar rates of nonresponse are seen in anxiety and PTSD treatments.

  • 5

    High rates of unfilled prescriptions and premature discontinuation of therapy contribute to suboptimal pharmacological outcomes in mental health.

Original Source(s)

At-Home Telehealth-Supported Subcutaneous Ketamine Therapy for Safety, Feasibility, and Clinical Outcomes in Adults With Moderate to Severe Depression, Anxiety, or Posttraumatic Stress Disorder in a Large, Heterogeneous Cohort in the United States: Retrospective Cohort Study

  • by Acacia C Parks, Amanda L Woodward, Robert D Henry, Kristin A Arden, Leonardo Vando, Jack Swain, Bishal Lamichhane

  • July 20, 2026

Related Content

What Tears Tell Us About Neurological Health

An experimental graphene-based device could support future noninvasive neurological biomarker testing from tear samples

  • July 16, 2026

  • 2 min
New CDC Report Tracks US Mortality Trends

The annual provisional report summarizes changes in mortality rates, demographic patterns, and leading causes of death during 2025.

Retraction: Metoprolol, N-Acetylcysteine, and Escitalopram Prevents Chronic Unpredictable Mild Stress-Induced Depression by Inhibition of Endoplasmic Reticulum Stress

  • July 15, 2026